IL174690A0 - Enhanced drug delivery - Google Patents

Enhanced drug delivery

Info

Publication number
IL174690A0
IL174690A0 IL174690A IL17469006A IL174690A0 IL 174690 A0 IL174690 A0 IL 174690A0 IL 174690 A IL174690 A IL 174690A IL 17469006 A IL17469006 A IL 17469006A IL 174690 A0 IL174690 A0 IL 174690A0
Authority
IL
Israel
Prior art keywords
drug delivery
enhanced drug
enhanced
delivery
drug
Prior art date
Application number
IL174690A
Other languages
English (en)
Original Assignee
Barnes Jewish Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barnes Jewish Hospital filed Critical Barnes Jewish Hospital
Publication of IL174690A0 publication Critical patent/IL174690A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909Micelles formed by phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1227Micelles, e.g. phospholipidic or polymeric micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL174690A 2003-11-19 2006-03-30 Enhanced drug delivery IL174690A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52383303P 2003-11-19 2003-11-19
PCT/US2004/039095 WO2005051305A2 (en) 2003-11-19 2004-11-19 Enhanced drug delivery

Publications (1)

Publication Number Publication Date
IL174690A0 true IL174690A0 (en) 2006-08-20

Family

ID=34632831

Family Applications (1)

Application Number Title Priority Date Filing Date
IL174690A IL174690A0 (en) 2003-11-19 2006-03-30 Enhanced drug delivery

Country Status (7)

Country Link
US (1) US20050175541A1 (https=)
EP (1) EP1684724A4 (https=)
JP (1) JP2007511616A (https=)
AU (1) AU2004293027A1 (https=)
CA (1) CA2540621A1 (https=)
IL (1) IL174690A0 (https=)
WO (1) WO2005051305A2 (https=)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044996A2 (en) * 2004-10-15 2006-04-27 The Trustees Of Columbia University In The City Of New York System and method for automated boundary detection of body structures
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
WO2006110745A2 (en) * 2005-04-08 2006-10-19 Cytogen Corporation Conjugated anti-psma antibodies
BRPI0611272A2 (pt) * 2005-05-03 2011-11-16 Mutual Pharmaceutical Co formulações de quinina
US10687785B2 (en) 2005-05-12 2020-06-23 The Trustees Of Columbia Univeristy In The City Of New York System and method for electromechanical activation of arrhythmias
CA2609373A1 (en) * 2005-05-23 2006-11-30 Mebiopharm Co., Ltd. Method of producing liposomes containing gas enclosed therein
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
EP1937151A4 (en) * 2005-09-19 2011-07-06 Univ Columbia Systems and methods for opening of the blood-brain barrier of a subject using ultrasound
JP5815915B2 (ja) * 2005-10-11 2015-11-17 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 過活動膀胱障害の治療のためのスフィンゴミエリンリポソーム
WO2007080453A2 (en) 2005-11-09 2007-07-19 Klox Technologies Inc. Teeth whitening compositions and methods
WO2007067987A2 (en) * 2005-12-09 2007-06-14 The Trustees Of Columbia University In The City Ofnew York Systems and methods for elastography imaging
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
NO20064315L (no) 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
US7947262B2 (en) * 2006-09-26 2011-05-24 Virginia Commonwealth University Use of fullerenes for the treatment of mast cell and basophil-mediated disease
US20100266989A1 (en) 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
CZ2006743A3 (cs) * 2006-11-28 2008-03-26 Fyziologický ústav AV CR Liposomální gelový ftalocyaninový prípravek pro fotodynamickou terapii nádorových onemocnení a zpusob jeho prípravy
WO2008109712A2 (en) 2007-03-05 2008-09-12 Washington University Nanoparticle delivery systems for membrane-integrating peptides
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
GB0721081D0 (en) 2007-10-26 2007-12-05 Metcalfe Susan M Immuno-modulatory composition
WO2009110939A2 (en) * 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
WO2011035312A1 (en) 2009-09-21 2011-03-24 The Trustees Of Culumbia University In The City Of New York Systems and methods for opening of a tissue barrier
US20100009424A1 (en) * 2008-07-14 2010-01-14 Natasha Forde Sonoporation systems and methods
WO2010014977A1 (en) 2008-08-01 2010-02-04 The Trustees Of Columbia University In The City Of New York Systems and methods for matching and imaging tissue characteristics
WO2010030819A1 (en) 2008-09-10 2010-03-18 The Trustees Of Columbia University In The City Of New York Systems and methods for opening a tissue
PL2352488T3 (pl) 2008-11-07 2017-07-31 Klox Technologies Inc. Utleniająca, aktywowana światłem kompozycja do odmładzania skóry zawierająca kwas hialuronowy, glukozaminę lub alantoinę
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
US20100178244A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
HUE035716T2 (en) 2009-07-17 2018-05-28 Klox Tech Inc Antibacterial oral composition
WO2011025893A1 (en) 2009-08-28 2011-03-03 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
WO2011035044A1 (en) * 2009-09-16 2011-03-24 University Of Kansas Fluorinated polymers and associated methods
WO2011075557A1 (en) * 2009-12-16 2011-06-23 The Trustees Of Columbia University In The City Of New York Methods, devices, and systems for on-demand ultrasound-triggered drug delivery
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
ES2711760T3 (es) * 2011-01-04 2019-05-07 Novaliq Gmbh Emulsiones de aceite/agua que comprenden alcanos semifluorados
WO2012135550A1 (en) * 2011-03-30 2012-10-04 Luna Innovations Incorporated Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
DK2714010T3 (en) 2011-05-25 2017-06-12 Novaliq Gmbh TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
WO2012162664A1 (en) 2011-05-26 2012-11-29 The Trustees Of Columbia University In The City Of New York Systems and methods for opening of a tissue barrier in primates
US11065206B2 (en) * 2011-06-29 2021-07-20 Avidas Pharmaceuticals, LLC Topical formulations including lipid microcapsule delivery vehicles and their uses
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US11116841B2 (en) 2012-04-20 2021-09-14 Klox Technologies Inc. Biophotonic compositions, kits and methods
US20130330389A1 (en) 2012-06-08 2013-12-12 The Regents Of The University Of Michigan Ultrasound-triggerable agents for tissue engineering
WO2014031883A1 (en) 2012-08-23 2014-02-27 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
KR20150082189A (ko) 2012-09-14 2015-07-15 밸리언트 파마슈티컬즈 인터내셔널, 인코퍼레이션 치아미백용 조성물 및 치아미백 방법
WO2014059170A1 (en) 2012-10-10 2014-04-17 The Trustees Of Columbia University In The City Of New York Systems and methods for mechanical mapping of cardiac rhythm
US20140276354A1 (en) 2013-03-14 2014-09-18 Klox Technologies Inc. Biophotonic materials and uses thereof
US9247921B2 (en) 2013-06-07 2016-02-02 The Trustees Of Columbia University In The City Of New York Systems and methods of high frame rate streaming for treatment monitoring
HK1219890A1 (zh) 2013-07-03 2017-04-21 广东科洛克生物医药集团有限公司 治疗不癒合伤口的组合物和方法
PT3024484T (pt) 2013-07-23 2018-10-24 Novaliq Gmbh Composições de anticorpo estabilizadas
US10322178B2 (en) 2013-08-09 2019-06-18 The Trustees Of Columbia University In The City Of New York Systems and methods for targeted drug delivery
US10028723B2 (en) 2013-09-03 2018-07-24 The Trustees Of Columbia University In The City Of New York Systems and methods for real-time, transcranial monitoring of blood-brain barrier opening
JP2017509433A (ja) 2014-04-01 2017-04-06 クロックス テクノロジーズ インコーポレイテッドKlox Technologies Inc. 組織充填剤組成物および使用方法
ES2856841T3 (es) 2014-10-31 2021-09-28 Klox Tech Inc Fibras y medios de tela fotoactivables
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
WO2017062502A1 (en) * 2015-10-05 2017-04-13 The Regents Of The University Of Colorgo, A Body Corporate Lipoplexes formulated for catalytic delivery
CA3015663A1 (en) * 2016-03-07 2017-09-14 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP4374851B1 (en) 2016-12-23 2026-04-15 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
JP7306718B2 (ja) 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
WO2019161263A1 (en) * 2018-02-16 2019-08-22 Ohio State Innovation Foundation Lipid-surfactant nanoparticles for drug delivery and methods of making and uses thereof
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
SG11202007860XA (en) 2018-03-28 2020-09-29 Novaliq Gmbh Pharmaceutical composition comprising timolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
US12050255B2 (en) * 2022-02-23 2024-07-30 Saudi Arabian Oil Company Magnetically activated acoustic nanotracers
TW202541849A (zh) * 2023-12-14 2025-11-01 美商聲納席拉公司 用於經由超音波改良核酸遞送之方法及系統

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US5690907A (en) * 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US6548046B1 (en) * 1995-06-08 2003-04-15 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6821506B2 (en) * 1995-06-08 2004-11-23 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6896659B2 (en) * 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US6716168B2 (en) * 2002-04-30 2004-04-06 Siemens Medical Solutions Usa, Inc. Ultrasound drug delivery enhancement and imaging systems and methods
US20030215394A1 (en) * 2002-05-17 2003-11-20 Short Robert E. Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream
US7358226B2 (en) * 2003-08-27 2008-04-15 The Regents Of The University Of California Ultrasonic concentration of drug delivery capsules

Also Published As

Publication number Publication date
WO2005051305A3 (en) 2005-08-04
EP1684724A4 (en) 2008-04-02
EP1684724A2 (en) 2006-08-02
WO2005051305A2 (en) 2005-06-09
JP2007511616A (ja) 2007-05-10
CA2540621A1 (en) 2005-06-09
US20050175541A1 (en) 2005-08-11
AU2004293027A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
IL174690A0 (en) Enhanced drug delivery
PL1631255T3 (pl) System dostarczania leków
GB2391480B (en) Drug delivery system
IL174748A0 (en) Nanoparticles for drug delivery
GB0319119D0 (en) Delivery devices
GB0320171D0 (en) Delivery devices
GB0400024D0 (en) Delivery devices
PL376169A1 (en) Drug delivery system
GB2385273B (en) Drug delivery device
GB2400565B (en) Nasal drug delivery
AP2006003602A0 (en) Oral drug delivery system
EG24425A (en) Drug delivery assembly
GB0308771D0 (en) Pulmonary drug delivery
GB2401043B (en) Drug
GB0329141D0 (en) Drug delivery
GB0311084D0 (en) Drug delivery
GB0401008D0 (en) Drug delivery system
EP1624073A4 (en) DRUG
GB0217478D0 (en) Multiple-therapy drug delivery
GB0209411D0 (en) Drug delivery
GB0313748D0 (en) Drug delivery compounds
HK1096587A (en) Enhanced drug delivery
GB0409506D0 (en) Drug delivery
GB0403558D0 (en) Drug delivery
GB0329041D0 (en) Nasal drug delivery